 Implantation human fetal ventral mesencephalon right caudate nucleus advanced Parkinson disease ventral mesencephalic tissue single human fetuses weeks gestation consistent striatal site patients advanced Parkinson disease optimum levodopa therapy months Immunosuppression significant sustained improvements months patients motor fluctuations absent modest group months increased quality phases quantity times specific improvements contralateral upper limb bradykinesia Preoperative levodopa requirements mean months months Deterioration baseline ratings patients consistent follow-up months midgestational human fetal tissue improvement Parkinson disease Individual disease severity critical trials host factors outcome